Company: TELO
Filing Date: 2025-02-14
Form Type: S-3
Source: 0001493152-25-006943
Chunk: 22

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-14
Form: S-3
Chunk 22
---
 if commenced, may be discontinued by the underwriters at any time.

The amount of expenses expected to be incurred by us in connection with any issuance of securities will be set forth in the applicable prospectus supplement.

Under Rule 15c6-l of the Exchange Act, trades in the secondary market generally are required to settle in two business days, unless the parties to any such trade expressly agree otherwise. Your prospectus supplement may provide that the original issue date for your securities may be more than three scheduled business days after the trade date for your securities. Accordingly, in such a case, if you wish to trade securities on any date prior to the third business day before the original issue date for your securities, you will be required, by virtue of the fact that your securities initially are expected to settle in more than three scheduled business days after the trade date for your securities, to specify alternative settlement arrangements to prevent a failed settlement.

Underwriters, agents and their affiliates may be customers of, engage in transactions with, or perform services for us or our subsidiaries in the ordinary course of their businesses. In connection with the distribution of the securities offered under this prospectus, we may enter into swap or other hedging transactions with, or arranged by, underwriters or agents or their affiliates. These underwriters or agents or their affiliates may receive compensation, trading gain or other benefits from these transactions.

<div align='center'>LEGAL MATTERS</div>

Unless otherwise indicated in the applicable prospectus supplements, certain legal matters in connection with any offering of securities made by this prospectus will be passed upon for us by Pearl Cohen Zedek Latzer Baratz LLP, New York, New York. If the securities are being distributed in an underwritten offering, certain legal matters will be passed upon for the underwriters by counsel identified in the related prospectus supplement.

<div align='center'>EXPERTS</div>

The financial statements of Telomir Pharmaceuticals, Inc. as of December 31, 2024 and for the year then ended included in the Annual Report on Form 10-K for the year ended December 31, 2024, have been incorporated by reference herein and in this prospectus in reliance upon the report of Salberg & Company P.A. (which report includes an explanatory paragraph regarding the existence of substantial doubt about the Company’s ability to continue as a going concern), independent registered public accounting firm, incorporated by reference herein, and given upon the authority of said firm as experts in accounting and auditing.

The financial statements of Telomir Pharmaceuticals